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STATE OF MAINE
KENNEBEC SS

SUPERIOR COURT
CIVIL ACTION
DOCKET NO. C V -2 1 -^ 3

STATE OF MAINE

)
)
)

Plaintiff,

)
)

v.

)

MCKINSEY & COMPANY, INC.
UNITED STATES,

)
)

CONSENT JUDGMENT
)

)
Defendant.

)

Plaintiff, the State of Maine (the “State” or “Plaintiff’) has filed a Complaint for
permanent injunction, damages and other relief in this matter pursuant to the Maine Unfair Trade
Practices Act, 5 M.R.S. § 209 alleging that Defendant McKinsey & Company, Inc. United States
(“McKinsey” or “Defendant”), committed violations of 5 M.R.S. §207. Plaintiff, by its counsel,
and McKinsey, by its counsel, have agreed to the entry of this Consent Judgment (“Judgment”)
by the Court without trial or adjudication of any issue of fact or law, and without finding or
admission of wrongdoing or liability of any kind.
IT IS H ER E BY O RDERED TH AT:
I. FIN D IN G S

A. For purposes of this proceeding only, this Court has jurisdiction over the subject matter
of this lawsuit and over the Parties (as defined below). This Judgment shall not be
construed or used as a waiver of any jurisdictional defense McKinsey may raise in any
other proceeding.
B. The terms of this Judgment shall be governed by the laws of the State of Maine.
C. Entry of this Judgment is in the public interest and reflects a negotiated agreement among
the Parties.

D. The Parties have agreed to resolve the issues resulting from the Covered Conduct (as
defined below) by entering into this Judgment.
E. McKinsey has cooperated with the Signatory Attorney General’s (as defined below)
investigation and is willing to enter into this Judgment regarding the Covered Conduct in
order to resolve the Signatory Attorney General’s claims and concerns under the Maine
Unfair Trade Practices Act, 5 M.R.S. §207 as to the matters addressed in this Judgment
and thereby avoid significant expense, inconvenience, and uncertainty.
F. “MultiState Executive Committee” means the Attorneys General and staffs representing
California, Colorado, Connecticut, Massachusetts, New York, North Carolina, Oregon,
Oklahoma, Tennessee, and Vermont.
G. The Signatory Attorney General acknowledges McKinsey’s good faith and responsible
corporate citizenship in reaching this resolution.
H. McKinsey is entering into this Judgment solely for the purpose of settlement, and nothing
contained herein may be taken as or construed to be an admission or concession of any
violation of law, rule, or regulation, or of any other matter of fact or law, or of any
liability or wrongdoing, all of which McKinsey expressly denies. McKinsey does not
admit any violation of the State Consumer Protection Laws (as defined below) and set
forth in footnote 1) and does not admit any wrongdoing that was or could have been
alleged by the Signatory Attorney General before the date of the Judgment. No part of
this Judgment, including its statements and commitments, shall constitute evidence of
any liability, fault, or wrongdoing by McKinsey.
I.

This Judgment shall not be construed or used as a waiver or limitation of any defense
otherwise available to McKinsey in any other action, or of McKinsey’s right to defend
itself from, or make any arguments in, any other regulatory, governmental, private
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individual, or class claims or suits relating to the subject matter or terms of this
Judgment. This Judgment is made without trial or adjudication of any issue of fact or law
or finding of liability of any kind. Notwithstanding the foregoing, the Signatory Attorney
General may file an action to enforce the terms of this Judgment.
J. No part of this Judgment shall create a private cause of action or confer any right to any
third party for violation of any federal or state statute except that the Signatory Attorney
General may file an action to enforce the terms of this Judgment. It is the intent of the
Parties that this Judgment shall not be binding or admissible in any other matter,
including, but not limited to, any investigation or litigation, other than in connection with
the enforcement of this Judgment. This Judgment is not enforceable by any persons or
entities besides the Signatory Attorney General, McKinsey and this Court.
II. D EFIN ITIO N S

The following definitions shall be used in construing the Judgment:
A. “Covered Conduct” means any and all acts, failures to act, conduct, statements, errors,
omissions, events, breaches of duty, services, advice, work, deliverables, engagements,
transactions, or other activity of any kind whatsoever, occurring up to and including the
Effective Date arising from or related in any way to (i) the discovery, development,
manufacture, marketing, promotion, advertising, recall, withdrawal, distribution,
monitoring, supply, sale, prescribing, reimbursement, use, regulation, or abuse of any
opioid, or (ii) the treatment of opioid abuse or efforts to combat the opioid crisis, or (iii)
the characteristics, properties, risks, or benefits of any opioid, or (iv) the spoliation of any
materials in connection with or concerning any of the foregoing.
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B. “Effective Date” means the date on which a copy of the Judgment, duly executed by
McKinsey and by the Signatory Attorney General, is approved by, and becomes a
Judgment of the Court.
C. “McKinsey” means McKinsey & Company, Inc. United States, a Delaware Corporation,
and all its current or former officers, directors, partners, employees, representatives,
agents, affiliates, parents, subsidiaries, operating companies, predecessors, assigns and
successors.
D. “Parties” means McKinsey and the Signatory Attorney General.
E. “Signatory Attorney General” means the Attorney General of Maine, or his/her
authorized designee, who has agreed to this Judgment.
F. “Settling State” means the state that has agreed to this Judgment.
G. “State Consumer Protection Laws” means the consumer protection laws cited in footnote
I .1*6

'ALABAMA - Alabama Deceptive Trade Practices Act § 8-19-1 et seq. (2002); ALASKA Alaska Unfair Trade Practices and Consumer Protection Act AS 45.50.471 - 45.50.561;
AMERICAN SAMOA - Consumer Protection Act, A.S.C.A. §§ 27.0401 et seq.; ARIZONA Consumer Fraud Act, A.R.S. §44-1521 et seq.; ARKANSAS - Arkansas Deceptive Trade
Practices Act, Ark. Code Ann. § 4-88-101, et seq.; CALIFORNIA - Bus. & Prof Code §§ 17200
et seq. and 17500 et seq.; COLORADO - Colorado Consumer Protection Act, Colo. Rev. Stat. §
6-1-101 et seq.; CONNECTICUT - Connecticut Unfair Trade Practices Act, Conn. Gen Stat. §§
42-110a through 42-1 lOq; DELAWARE - Delaware Consumer Fraud Act, Del. CODE ANN. tit.
6, §§ 2511 to 2527; DISTRICT OF COLUMBIA, District of Columbia Consumer Protection
Procedures Act, D.C. Code §§ 28-3901 et seq.; FLORIDA - Florida Deceptive and Unfair Trade
Practices Act, Part II, Chapter 501, Florida Statutes, 501.201 et. seq.; GEORGIA - Fair Business
Practices Act, O.C.G.A. Sections 10-1-390 et seq.; GUAM - Trade Practices an d Consum er
Protection, 5 G.C.A. Ch. 32 et seq.; HAWAII - Uniform Deceptive Trade Practice Act, Haw.
Rev. Stat. Chpt. 481A and Haw. Rev. Stat. Chpt. 480; IDAHO - Idaho Consumer Protection Act,
Idaho Code § 48-601 et seq.; ILLINOIS - Consumer Fraud and Deceptive Business Practices
Act, 815 ILCS 505/2 et seq.; INDIANA - Deceptive Consumer Sales Act, Ind. Code §§ 24-50.5-0.1 to 24-5-0.5-12; IOWA - Iowa Consumer Fraud Act, Iowa Code Section 714.16;
KANSAS - Kansas Consumer Protection Act, K.S.A. 50-623 et seq.; KENTUCKY - Kentucky
Consumer Protection Act, KRS Ch. 367.110, et seq.; LOUISIANA - Unfair Trade-Practices and
4

H. Any reference to a written document shall mean a physical paper copy of the document,
electronic version of the document, or electronic access to such document.
III. IN JU N C T IV E RELIEF

It is ordered that:
A. McKinsey shall not accept any future engagements relating to the
discovery, development, manufacture, marketing, promotion, advertising, recall,
withdrawal, monitoring, sale, prescribing, use or abuse of any

Consumer Protection Law, LSA-R.S. 51:1401, et seq.; M A IN E-U nfair Trade Practices Act, 5
M.R.S.A. § 207 et seq.; MARYLAND - Maryland Consumer Protection Act, Md. Code Ann.,
Com. Law §§ 13-101 et seq.; MASSACHUSETTS - Mass. Gen. Laws c. 93A, §§ 2 and 4;
MICHIGAN - Michigan Consumer Protection Act, MCL § 445.901 et seq.; MINNESOTA Minn. Stat. §§325D.44, 325F.69; MISSISSIPPI - Mississippi Consumer Protection Act, Miss.
Code Ann.§ 75-24-1, et seq.; MISSOURI - Missouri Merchandising Practices Act, Mo. Rev.
Stat. §§ 407.010 et seq.; MONTANA - Montana Consumer Protection Act §§ 30-14-101 et seq.;
NEBRASKA - Consumer Protection Act, Neb. Rev. Stat. §§ 59-1601 et seq. and Uniform
Deceptive Trade Practices Act, Neb. Rev. Stat. §§ 87-301 et seq.;; NEW HAMPSHIRE -N H
RSA §358-A et seq; NEW JERSEY - New Jersey Consumer Fraud Act, NJSA 56:8-1 et seq.;
NEW MEXICO - NMSA 1978, §57-12-1 et seq.; NEW Y O RK -G eneral Business Law Art.
22-A, §§ 349-50, and Executive Law § 63(12); NORTH CAROLINA - North Carolina Unfair
and Deceptive Trade Practices Act, N.C.G.S. § 75-1.1, et seq.; NORTH DAKOTA-Unlawful
Sales or Advertising Practices, N.D. Cent. Code § 51-15-02 et seq.; NORTHERN MARIANA
ISLANDS - Consumer Protection Act, 4 N. Mar. I. Code §§ 5201 et seq.; OHIO - Ohio
Consumer Sales Practices Act, R.C. 1345.01, et seq.; OKLAHOMA - Oklahoma Consumer
Protection Act 15 O.S. §§ 751 et seq.; OREGON - Oregon Unlawful Trade Practices Act, Or.
Rev. Stat. § 646.605 et seq.; PENNSYLVANIA - Pennsylvania Unfair Trade Practices and
Consumer Protection Law, 73 P.S. 201-1 et seq.; PUERTO RICO - Puerto Rico Antitrust Act,
10 L.P.R.A. § 259; RHODE ISLAND - Deceptive Trade Practices Act, Rhode Island Gen. Laws
§ 6-13.1-1, et seq.; SOUTH CAROLINA - South Carolina Unfair Trade Practices Act, S.C.
Code Ann. § 39-5-10 et seq.; SOUTH DAKOTA - South Dakota Deceptive Trade Practices and
Consumer Protection, SDCL ch. 37-24; TENNESSEE - Tennessee Consumer Protection Act,
Tenn. Code Ann. 47-18-101 et seq.; TEXAS - Texas Deceptive Trade Practices-Consumer
Protection Act, Tex. Bus. And Com. Code 17.41, et seq.; UTAH - Consumer Sales Practices Act,
Utah Code Ann. §§ 13-11-1 et seq.; VERMONT - Vermont Consumer Protection Act, 9 V.S.A.
§ 2451, et seq.; VIRGIN ISLANDS - Virgin Islands Consumer Protection Law, 12A V.I.C. §§
101 et seq.; VIRGINIA-Virginia Consumer Protection Act, Va Code Ann. §59.1-196 et seq.;
WISCONSIN - Wis. Stat. § 100.18 (Fraudulent Representations); WYOMING - Wyoming
Consumer Protection Act, Wyo. Stat. Ann. §§ 40-12-101 through -114.
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Opioid or other opioid-based Schedule II or III controlled substance;
B. Nothing in Section III.A above is intended to prohibit McKinsey from offering its
services to: ( 1) clients who, as part of their overall business, develop, manufacture,
market, promote, advertise, recall, withdraw, distribute, monitor, supply, sell or prescribe
opioids or other opioid-based Schedule II or III controlled substances, so long as the
subject matter of the engagement does not specifically relate to opioids or other opioidbased Schedule II or III controlled substances; or (2) health care providers, health plans,
non-profit entities, governments, and quasi-govemmental agencies, or any other client
that is not a pharmaceutical manufacturer, for purposes of addressing a humanitarian
health crisis, drug abuse prevention, treatment, and mitigation or abatement efforts, or
other public health benefit;
C. Within eighteen months of the Effective Date for paragraph 4 below, and within twentyfour months of the Effective Date for paragraphs 1-3 below, McKinsey shall develop and
implement a document retention policy that provides as follows:
1. McKinsey shall maintain a centralized document storage system (“Storage
System”) such as a document management system or a file sharing platform.
2. Unless prohibited by state, federal, or foreign law, McKinsey shall require its
partners and employees, to the extent possible on a best-efforts basis, to create
and maintain a final working papers file (“Final Working Papers File”) relating to
client engagements on the Storage System. The Final Working Papers File shall
include, but not be limited to, letters of proposal, contracts, memoranda, invoices,
contracted deliverables, and close-out memoranda.
3. McKinsey shall retain the Final Working Papers File for a minimum of seven
years.
6

4. McKinsey shall retain all communications and documents exchanged on any
electronic mail (including associated attachments) or instant message system that
McKinsey authorizes its personnel to use for five years;
5. Nothing in this section shall prevent McKinsey from: (a) deleting documents or
data as required by any state, federal, or foreign law or regulation, or (b) deleting
documents or data as contractually required by a third party where such
contractual requirement is reasonably necessary to allow the third party to comply
with any state, federal, or foreign law or regulation.
D. McKinsey shall implement a written policy requiring the termination of any employee
that engages in the intentional spoliation of evidence for an improper purpose;
E. In the next calendar year after the Effective Date, McKinsey shall include in the annual
acknowledgement that all McKinsey partners are required to certify a section describing
the terms and conditions of this Judgment, and McKinsey shall further hold additional
annual training for partners in the Pharmaceuticals & Medical Products practice
concerning the terms and conditions of this Judgement;
F. Revisions to Client conflict policy pertaining to Government Clients (defined below),
which shall be implemented within 60 days of the Effective Date.
1. McKinsey agrees to revise its conflict policy pertaining to potential engagements by
any Settling State, county government, or municipal government (or any government
agency of the aforementioned) (“Government Client”) to require a written disclosure
of any material conflict (“Conflict Disclosure”) when (A) responding in writing to a
request for proposal; (B) formally proposing work; (C) tendering an engagement
letter to a Government Client; or (D) beginning work for a Government Client in the
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absence of an engagement letter, proposal, or request for proposal, whichever occurs
first (“Triggering Event”).
2. A material conflict exists for purposes of this Section III.F when, at the time of any
Triggering Event, McKinsey is advising or in the past three years has previously
advised an industry client on work which, in the view of a neutral and detached
observer, is or was materially adverse to the work McKinsey would perform for the
Government Client, such that when McKinsey is working or has worked to advance
the goals or interests of the industry client it is likely to harm the goals or interests it
is working to advance of the Government Client.
3. Within 90 days of the Effective Date, McKinsey shall review each current
engagement with a Government Client and provide a Conflict Disclosure where it
would be otherwise required under this Section III.F for a new Government Client.
4. Nothing in this Section III.F shall supersede or affect any legal or contractual
obligation McKinsey may have pertaining to confidentiality, conflicts, or
engagement of clients (“Client Obligations”). The Conflict Disclosure shall not
require McKinsey to violate any confidentiality obligations McKinsey has with its
clients, and McKinsey satisfies its obligations under this section by providing a
Conflict Disclosure (A) identifying the relevant industry; and (B) generally
describing the work McKinsey performs for its industry client (without identifying
its client). If for whatever reason McKinsey determines that its Client Obligations
preclude a Conflict Disclosure, McKinsey agrees to decline the work for the
Government Client.
G. McKinsey shall not use, assist, or employ any Third Party to engage in any activity that
McKinsey itself would be prohibited from engaging in pursuant to this Judgment.
8

H. The foregoing injunctive terms may be amended by agreement between McKinsey and
the State of Maine without this Court’s approval or amendment of this Judgment.
IV . PU BLIC A C C E SS TO M C K IN SE Y DO CUM ENTS

It is ordered that:
A. D ocum ents Subject to P ub lic D isclosure

1. The following documents shall be produced by McKinsey to each Settling State and are
subject to public disclosure in perpetuity as part of a document disclosure program, except for
the redactions authorized by Section B:
All non-privileged documents McKinsey produced to any of the Settling States in response to
investigative demands or other formal or informal requests related to opioids in 2019, 2020, or
2021, prior to the date of this Judgment, that fall within the following categories:
a. All communications with Purdue Pharma LP (“Purdue”);
b. All documents reflecting or concerning McKinsey’s work for Purdue;
c. All communications with Endo Pharmaceuticals (“Endo”), Johnson & Johnson, or
Mallinckrodt Pharmaceuticals (“Mallinckrodt”) related to opioids;
d. All documents reflecting or concerning McKinsey’s work related to opioids for Endo,
Johnson & Johnson, or Mallinckrodt^
e. All documents and communications sent or received by individual consultants agreed
upon by McKinsey and the Settling States related to opioids or the opioid crisis;
f. All documents listed by Bates number in Appendix A.
2.

All documents produced under this provision shall be provided in electronic format

with all related metadata. McKinsey and the Settling States will work cooperatively to develop
technical specifications for the productions.
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B. Inform ation T hat M ay B e R edacted

The following categories of information are exempt from public disclosure:
1. Information subject to trade secret protection. A “trade secret” is information, including a
formula, pattern, compilation, program, device, method, technique or process, that (a) derives
independent economic value, actual or potential, from not being generally known to the public or
to other persons who can obtain economic value from its disclosure and use; and (b) is the
subject of efforts that are reasonable under the circumstances to maintain its secrecy. Even if the
information falls within the definition, “trade secret” does not include information reflecting
opioid sales or promotional strategies, tactics, targeting, or data, or internal communications
related to sales or promotion of opioidsv
2. Confidential personal information. “Confidential personal information” means individual
Social Security or tax identification numbers, personal financial account numbers, passport
numbers, driver license numbers, home addresses, home telephone numbers, personal email
addresses, and other personally identifiable information protected by law from disclosure.
“Confidential personal information” does not include the names of officers, directors, employees,
agents, or attorneys o f McKinsey, Purdue, Endo, Johnson & Johnson, or Mallinckrodt, or of a
government agency.
3. Information that is inappropriate for public disclosure because it is subject to personal privacy
interests recognized by law (e.g., HIPAA), or contractual rights of third parties (including
McKinsey’s clients) that McKinsey may not abrogate. McKinsey shall make its best efforts to
ensure that disclosure into the document repository is not limited or prohibited by contractual
rights of Purdue with regard to any documents, or by contractual rights of Endo, Johnson &
Johnson, or Mallinckrodt with regard to documents related to opioids.
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4. Information regarding McKinsey partners’ or employees’ personal or professional matters
unrelated to McKinsey or opioids, including but not limited to emails produced by McKinsey
custodians discussing vacation or sick leave, family, or other personal matters.
C. R edaction o f D ocum ents C ontaining Protected Inform ation

1. Whenever a document contains information subject to a claim of exemption pursuant to
Section B, McKinsey shall produce the document in redacted form. Such redactions shall
indicate that trade secret and/or private information, as appropriate, has been redacted.
Redactions shall be limited to the minimum redactions possible to protect the legally recognized
individual privacy interests and trade secrets identified above.
2. McKinsey shall produce to each Settling State a log noting each document redacted. The log
shall also provide fields stating the basis for redacting the document, with sufficient detail to
allow an assessment of the merits of the assertion. The log is subject to public disclosure in
perpetuity. The log shall be produced simultaneously with the production of documents required
by Section IV.F.
3. In addition to the redacted documents, McKinsey shall, upon any Settling State’s request, also
produce all documents identified in Section IV.A above in unredacted form to such Settling State
at the same time. The redacted documents produced by McKinsey may be publicly disclosed in
accordance with Section IV.E below. The unredacted documents produced by McKinsey to a
Settling State shall be available only to such State unless McKinsey’s claim of exemption under
Section IV.B is successfully challenged in accordance with Section IV.C.4 or the trade secret
designation expires in accordance with Section IV.D.
4. Anyone, including members of the public and the press, may challenge the appropriateness of
redactions by providing notice to McKinsey and a Settling State, which Settling State shall
review the challenge and inform McKinsey of whether the challenge has sufficient merit to
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warrant triggering the remaining provisions of this paragraph. If the challenge is not resolved by
agreement, it must be resolved in the first instance by a third party jointly appointed by the
Settling State and McKinsey to resolve such challenges. The decision of the third party may be
appealed to a court with enforcement authority over this Judgment. If not so appealed, the third
party’s decision is final. In connection with such challenge, a Settling State may provide copies
of relevant unredacted documents to the parties or the decisionmaker, subject to appropriate
confidentiality and/or in camera review protections, as determined by the decisionmaker.
D. R eview o f T rade Secret R edactions

Seven years after McKinsey completes the production of its documents in accordance with
Section IV.F and upon notice by a Settling State, McKinsey shall review all trade secret
assertions made in accordance with Section IY.B—The newly unredacted documents may then be
publicly disclosed by a Settling State in accordance with Section IV.E. McKinsey shall produce
to each Settling State an updated redaction log justifying its designations of the remaining trade
secret redactions.
E. P ub lic D isclosure through a D ocum ent R epository
Each Settling State may publicly disclose all documents covered by Section IV.A through a
public repository maintained by a governmental, non-profit, or academic institution. Each
Settling State may specify the terms of any such repository’s use of those documents, including
allowing the repository to index and make searchable all documents subject to public disclosure,
including the metadata associated with those documents. When providing the documents
covered by Section IV.A to a public repository, no Settling State shall include or attach within
the document set any characterization of the content of the documents. For the avoidance of
doubt, nothing in this paragraph shall prohibit any Settling State from publicly discussing the
documents covered by Section IV.A.
12

F. Timeline for Production
McKinsey shall produce all documents required by Section IV.A within nine months from the
Effective Date.
G. C osts

The Settling States may allocate funds from the Settlement to fund the allocable share of all
reasonable costs and expenses associated with the public disclosure and storage of McKinsey’s
documents through any public repository.
V. PA Y M EN T

1.

McKinsey shall pay a total amount of $573,919,331 (“the Settlement Amount”). Of the

Settlement Amount, $558,919,331 shall be allocated among the Settling States as agreed to by
the Settling States. It is the intent of the Parties that the $558,919,331 paid to the participating
States will be used, to the extent practicable, to remediate the harms caused to the Settling States
and their citizens by the opioid epidemic within each State and to recover the costs incurred by
the Settling State in investigating and pursuing these claims.2 McKinsey shall pay the
$15,000,000 balance of the Settlement Amount to the National Association of Attorneys General
(“NAAG Fund”). The NAAG Fund shall be used: first, to reimburse NAAG for the costs and
expenses of the States’ opioid investigations in the amount of $7,000,000 and second to
reimburse participating States for documented costs and expenses associated with the
investigation of McKinsey submitted by or before March 1, 2021, subject to reasonable
parameters to be set by NAAG. The remaining balance of the NAAG Fund shall be used to fund

2 Maine’s share o f the settlement is $3,139,915.00. The payment to the State o f Maine shall be deposited to the
special revenue account described in 5 M.R.S. § 203-A to be used by the Attorney General pursuant to that statute for
opioid remediation purposes that are evidence based, such as expanding availability o f treatment, including
Medication Assisted Treatment (MAT) for Opioid Use Disorder (OUD) and any co-occurring substance use or mental
health issues, supportive housing, recovery case management and residential treatment, addressing the needs o f
persons involved in the criminal justice system who have OUD, and paying costs o f litigating future cases arising
under Maine’s consumer protection laws, including costs for experts and personnel.
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the establishment of an online repository of opioid industry documents for the benefit of the
public.
2.

McKinsey shall pay a total amount of $573,919,331 as follows: 1) the initial payment of

$478,266,111 including the $15,000,000 payment to NAAG, shall be paid by 60 days after the
Effective Date; 2) the second payment of $23,913,305 shall be paid no later than one year from
the date of the initial payment; 3) the third payment of $23,913,305 shall be paid no later than
two years from the date o f the initial payment; 4) the fourth payment of $23,913,305 shall be
paid no later than three years from the date of the initial payment; and 5) the fifth payment of
$23,913,305 shall be paid no later than four years from the date of the initial payment.
3.

McKinsey will not seek indemnification from any entity with respect to this Judgment,

provided, however, that the foregoing limitation shall not be construed to apply to any claim by
McKinsey under any policies or contracts of insurance insuring McKinsey.
V I.

ENFO RCEM ENT

A. For the purposes of resolving disputes with respect to compliance with this Judgment,
should any of the Signatory Attorneys General have a reasonable basis to believe that
McKinsey has engaged in a practice that violates a provision of this Judgment subsequent
to the Effective Date, then such Signatory Attorney General shall notify McKinsey in
writing of the specific objection, identify with particularity the provision of this
Judgment/Order that the practice appears to violate, and give McKinsey 30 days to
respond to the notification; provided, however, that a Signatory Attorney General may
take any action if the Signatory Attorney General believes that, because of the specific
practice, a threat to the health or safety of the public requires immediate action.
B. Upon receipt of written notice, McKinsey shall provide a good faith written response to
the Signatory Attorney General’s notification, containing either a statement explaining
14

why McKinsey believes it is in compliance with the Judgment, or a detailed explanation
of how the alleged violation occurred and a statement explaining how McKinsey intends
to remedy the alleged breach. Nothing in this section shall be interpreted to limit the
State of Maine’s civil investigative demand (“CID”) or investigative subpoena authority,
to the extent such authority exists under applicable law, and McKinsey reserves all o f its
rights in responding to a CID or investigative subpoena issued pursuant to such authority.
C. The Signatory Attorney General may agree, in writing, to provide McKinsey with
additional time beyond the 30 days to respond to a notice provided under section V.A.
above without Court approval.
D. Upon giving McKinsey 30 days to respond to the notification described above, the
Signatory Attorney General shall also be permitted reasonable access to inspect and copy
relevant, non-privileged, non-work product records and documents in the possession,
custody, or control of McKinsey that relate to McKinsey’s compliance with each
provision of this Judgment/Order pursuant to that State’s CID or investigative subpoena
authority.
E. The Signatory Attorney General may assert any claim that McKinsey has violated this
Judgment in a separate civil action to enforce compliance with this Judgment, or may
seek any other relief afforded by law for violations of the Judgment, but only after
providing McKinsey an opportunity to respond to the notification described in paragraph
V.A above; provided, however, that a Signatory Attorney General may take any action if
the Signatory Attorney General believes that, because of the specific practice, a threat to
the health or safety of the public requires immediate action.
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VII. RELEASE
A. Released Claims. By its execution of this Judgment, the State of Maine releases and
forever discharges McKinsey and its past and present officers, directors, partners,
employees, representatives, agents, affiliates, parents, subsidiaries, operating companies,
predecessors, assigns and successors (collectively, the “Releasees”) from the following:
all claims the Signatory Attorney General is authorized by law to bring arising from or
related to the Covered Conduct, including, without limitation, any and all acts, failures to
act, conduct, statements, errors, omissions, breaches of duty, services, advice, work,
engagements, events, transactions or other activity of any kind whatsoever occurring up
to and including the effective date of the Judgment. Released claims will include,
without limitation, claims that were or could have been brought by a Settling State under
its State’s consumer protection and unfair trade practices law, RICO laws, false claims
laws and claims for public nuisance, together with any related common law and equitable
claims for damages or other relief.
B. Claims Not Covered: Notwithstanding any term of this Judgment, specifically reserved
and excluded from the release in Paragraph VII. A. as to any entity or person, including
Released Parties, are any and all o f the following:
1.

Any criminal liability that any person and/or entity, including Released Parties, has
or may have to the State of Maine.

2.

Any civil or administrative liability that any person and/or entity, including Released
Parties, has or may have to the State of Maine not covered by the release in
Paragraph V.A above, including the following claims:
(a) state or federal antitrust violations;
(b) any claims arising under state tax laws;
16

(c) any claims arising under state securities laws;
(d) any action to enforce this consent judgment and any subsequent related
orders and judgments.
3.

Any liability under the State of Maine State Consumer Protection Laws which any
person and/or entity, including Released Parties, has or may have to individual
consumers. Nothing herein precludes the Released Party from asserting any claims
or defenses that may be available to it under the law in any court action.

V III. A D D ITIO N A L PR O V ISIO N S

A. Nothing in this Judgment shall be construed to authorize or require any action by
McKinsey in violation of applicable federal, state, or other laws.
B. Modification. This Judgment may be modified by a stipulation of the Parties as
approved by the Court, or by court proceedings resulting in a modified judgment of the
Court, except to the extent as otherwise provided herein. For purposes of modifying this
Judgment, McKinsey may contact any member of the MultiState Executive Committee
for purposes of coordinating this process.
C. The acceptance of this Judgment by the State of Maine shall not be deemed approval by
the State of Maine of any of McKinsey’s business practices. Further, neither McKinsey
nor anyone acting on its behalf shall state or imply, or cause to be stated or implied, that
the State of Maine or any other governmental unit of the State of Maine has approved,
sanctioned or authorized any practice, act, or conduct of McKinsey.
D. Any failure by any party to this Judgment to insist upon the strict performance by any
other party of any of the provisions of this Judgment shall not be deemed a waiver of any
of the provisions of this Judgment, and such party, notwithstanding such failure, shall
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have the right thereafter to insist upon the specific performance of any and all of the
provisions of this Judgment.
E. Entire Agreement: This Judgment represents the full and complete terms of the settlement
entered into by the Parties hereto, except as the parties have otherwise agreed. In any
action undertaken by the Parties, no prior versions of this Judgment and no prior versions
of any of its terms that were not entered by the Court in this Judgment, may be introduced
for any purpose whatsoever.
F. Jurisdiction: This Court retains jurisdiction of this Judgment and the Parties hereto for the
purpose of enforcing and modifying this Judgment and for the purpose of granting such
additional relief as may be necessary and appropriate.
G. If any provision of this Judgment shall be held unenforceable, the Judgment shall be
construed as if such provision did not exist.
H. Counterparts: This Judgment may be executed in counterparts, and a facsimile or .pdf
signature shall be deemed to be, and shall have the same force and effect as, an original
signature.
I.

Notice: All Notices under this Judgment shall be provided to the following via email and
Overnight Mail:
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Defendant:
James Bernard, Esq.
Stroock & Stroock & Lavan LLP
180 Maiden Lane
New York, NY 10038
MAINE ATTORNEY GENERAL
AARON M. FREY

Linda Conti Me. Bar No. 3638
Brendan F.X. O’Neil, Bar No. 9900
Assistant Attorneys General
6 State House Station
Augusta, ME 04333
207 626-8800

Jonathan Slonim
Assistant Secretary
McKinsey & Company, Inc. United States
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February 4, 2021
Date

Local Counsel for McKinsey & Company, Inc. United States

February 4, 2021
Date

Elaine Epstein
Ingrid Martin
Todd & Weid LLP
One Federal Street
Boston, MA 02110
Ph (617) 624-4761
eepstein@toddweld.com
imartin@toddweld.com
I j r t« T>1 r~\ <« 4-1-PP C + n +a <-i-P A yf m-MQ

Date

Linda Conti, ME Bar No. 3638
Brendan F.X. O’Neil, Bar No. 9900
Assistant Attorneys General
6 State House Station
Augusta, ME 04333
207 626 8800
Attorneys for Plaintiff
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R egional O ffices
84 H arlow St . 2 nd F loor
B angor, M aine 04401
T el: (207) 941-3070
Fax: (207) 941-3073
A

a r o n M . F r e
ATTORNEY GENERAL

y

TEL: (207) 626 -8 8 0 0
TTY U S E R S C A L L M A I N E R E L A Y 711

125 P resumpscot St ., S uite 26
P ortland, Maine 04103
T el: (207) 822-0260
F a x : (207) 822-0259
S t a t e of M a i n e
O ffi ce of t h e A t t o r n e y G e n e r a l
6 S t a t e H ouse S t a t i o n
A u g u s t a , M aine 0 4 3 3 3 - 0 0 0 6

14 A ccess H ighway, S te . 1
C aribou, M aine 04736
T el: (207) 496-3792
Fax: (207) 496-3291

February 4, 2021

HAND DELIVERED
Michele Lumbert, Clerk
Kennebec County Superior Court
Capital Judicial Center
1 Court Street, Suite 101
Augusta, Maine 04330
RE:

State of Maine v. McKinsey Company, Inc., United States
Civil Action Docket No. CV-21-

Dear Michele:
Enclosed for filing in the above captioned matter, please find a Complaint, Consent
Judgment and Summary Sheet. Please bring this to the Court’s attention at your earliest
convenience.
Thank you for your assistance in this matter. If you have any questions in this matter, my
direct line is 207 441-2167.
Sincèrely, ;
x
/

Assistant Attorney General
LJC/gac
Enclosures
Cc: eepstein@toddweld.com (via email)
imartin@toddweld.com (via email)
mcarrigan@hollandhart.com (via email)
ibemard@strook.com (via email)
snewman@strook.com (via email)

SUPERIOR COURT
CIVIL ACTION
DOCKET NO . CV -21-

STATE OF M AINE
KENNEBEC SS.

)
)

STATE OF M AINE
Plaintiff,

)
)
)

V.

COMPLAINT

)

M CKINSEY COM PANY, INC.,
UNITED STATES,

)

)

Defendant.

C om es now the Plaintiff, the State o f M aine, and brings this action against Defendant
M cKinsey and Company, Inc., U nited States (“M cK insey” or “D efendant”) for violating the M aine
Unfair Trade Practices A ct, 5 M .R .S. §§ 205-A et seq., and states as follow s:

I.
1.

PARTIES

Plaintiff is the State o f M aine acting by its Attorney General Aaron M . Frey. The

Attorney General is charged w ith, among other things, enforcing and seeking redress for violations
o f the M aine Unfair Trade Practices A ct, 5 M .R.S. § 207.
2.

The Attorney General is authorized to bring this action pursuant to 5 M .R.S. § 209

and in his parenspatriae capacity to act in the public interest pursuant to com m on law. The State o f
M aine is a legal entity and has suffered damages and losses as a direct and proximate result o f
M cK insey’s conduct.
3.

Defendant M cK insey is a privately ow ned entity headquartered in N ew York, N . Y.

A t all tim es relevant to this proceeding, M cK insey transacted business in M aine.

II,
4.

JURISDICTION AND VENUE

The Court has jurisdiction over the Defendant pursuant to 14 M .R.S. § 704>A

because M cK insey has transacted business w ithin the state o f M aine at all tim es relevant to this
Complaint.
5.

Venue for this action properly lie s in Kennebec County pursuant to 5 M .R.S. §209.

III.
6.

FACTS

Beginning in the m id-1990s, opioid manufacturers pursued aggressive sales

strategies to increase sales o f their prescription opioids, a plan that resulted in a dramatic rise in
opioid prescriptions in M aine. The rise in opioid prescriptions caused an equally devastating rise in
opioid abuse, dependence, addiction, and overdose deaths.
7.

Prescription opioids continue to kill people across M aine every year. Many more

suffer from negative health consequences short o f death and countless others have had their lives
ruined by a friend or fam ily member’s addiction or death. Every com m unity in M aine suffers from
the opioid crisis o f addiction and death.
8.

M cK insey worked with entities involved in manufacturing and selling opioids and

thereby contributed to the opioid crisis.
9.

M cK insey is one o f the w orld’s largest consulting com panies. Its partners work

w orldwide for corporations and governments across diverse industries. Its influence is vast because
o f its best-in-class reputation. M cK insey sells the notion that it can take whatever a company or
governm ent is doing and make them do it better.
10.

The State brings this action against M cK insey for the consulting services it provided

to opioid com panies in connection with designing the com panies’ m arketing plans and programs
that helped cause and contributed to the opioid crisis. M cK insey sold its ideas to OxyContin maker
Purdue Pharma, L.P. (“Purdue”) for more than fifteen years, from 2004 through 2019, including
before and after Purdue’s 2007 guilty plea for felony misbranding.

2

11.

M cK insey advised Purdue and other manufacturers to target prescribers who write

the m ost prescriptions, for the m ost patients, and thereby make the m ost m oney for M cK insey’s
clients.
12.

Early in their relationship, M cK insey advised Purdue that it could increase

OxyContin sales through physician targeting and specific m essaging to prescribers. These
M cK insey strategies formed the pillars o f Purdue’s sales tactics for the next fifteen years.
13.

In 2008, M cK insey worked w ith Purdue to develop its FDA mandated risk

evaluation and m itigation strategy (“REM S”). M cK insey advised Purdue to “band together” with
other opioid manufacturers toward a class REM S to “formulate arguments to defend against strict
treatment by the FD A .” U ltim ately, the FD A adopted a class-w ide REMS that resulted in high-dose
OxyContin rem aining subject to the same oversight as low er-dose opioids.
14.

In 2009, Purdue hired M cK insey to increase “brand loyalty” to OxyContin.

M cK insey recom m ended the best ways to ensure loyalty to the brand by targeting specific patients,
including patients new to opioids, and developing targeted m essaging for specific prescribers.
15.

Purdue thereafter adopted M cK insey’s proposed prescriber m essaging and patient

targeting advice and incorporated them into Purdue’s marketing and sales strategies.
16.

In 2013, M cK insey conducted another analysis o f O xycontin growth opportunities

for Purdue and laid out new plans to increase sales o f OxyContin. Am ong the key com ponents o f
M cK insey’s plan w ere to:
a. focus sales calls on high-volum e opioid prescribers, including those who wrote as
m any as 25 tim es as m any O xyContin scripts as their low er volum e counterparts;
b . rem ove sales representative discretion in target prescribers;
c. focus Purdue’s marketing m essaging to titrate to higher, more lucrative dosages;
3

d. significantly increase the number o f sales visits to high-volum e prescribes; and
e.

create an “alternative m odel for how patients receive OxyContin,” including
direct distribution to patients and pharm acies, to help address the “product access”
problem.

17.

Purdue approved M cK insey’s plan, and together with M cK insey, m oved to

im plem ent the plan to “Turbocharg[e] Purdue’s Sales Engine,” under the nam e E volve 2 Excellence
(“E2E”). E2E significantly increased Purdue’s O pioid Sales in particular, for OxyContin.
18.

M cK insey partners participated as part o f an Executive O versight Team and Project

M anagement O ffice, reporting to Purdue’s Executive, the Purdue board, and w ith the Sacklers,
individually. M cK insey worked side by side w ith Purdue and helped Purdue plan and implement
E2E, assisting w ith sales representative training, productivity, m essaging, and call plans, IT
system s, prom otional strategies, and market forecasting.
19.

In developing the targeted m essaging to increase sales o f O xyContin, M cKinsey

conducted significant market research, including through ride-alongs w ith Purdue sales
representatives to learn how they promoted O xyContin. M cKinsey carefully m onitored Purdue sales
representatives and provided guidance on prescriber m essaging and adhering to target prescriber
lists. M cK insey advised that sales representatives do more to promote the supposed abuse deterrent
properties o f a reformulated version o f O xyContin to address prescriber concerns about abuse risk.
20.

W hen a large pharmacy chain took steps to scrutinize suspicious opioid orders,

M cK insey stressed to Purdue’s owners the “need to take action” on this “urgent” issue affecting
OxyContin. M cK insey told Purdue’s owners to engage in senior level discussions w ith the
pharmacy chain, increase efforts w ith patient advocacy groups to clamor against dispensing lim its,
and accelerate considerations o f an alternative distribution channel, such as delivering OxyContin
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directly to patients through mail-order pharmacies,
21.

After E2E, M cK insey continued to work with Purdue, including on aproject that

identified the growing addiction crisis as a profit-m aking opportunity. M cKinsey told Purdue that it
should strive to becom e a provider across the spectrum o f drug abuse and addiction because o f the
opportunities it presented. M cKinsey advised Purdue to get into the manufacturing and marketing o f
opioid rescue and treatm ent m edications in order to profit from the realities o f dependence,
addiction, and abuse. Indeed, in 2018, Purdue owner Dr. Richard Sackler received a patent for a
drug to treat opioid addiction.
22.

M cK insey also partnered with Purdue to test a program called FieldG uide, a

proprietary softw are that M cK insey sought to licen se to other manufacturers. This software would
enable other opioid manufacturers to target and aggressively pursue high-volum e prescribers.
23.

M cK insey continued to design and develop w ays that Purdue could increase sales o f

OxyContin w ell after the opioid epidem ic peaked. One proposal M cK insey recom m ended w as for
Purdue pay “additional rebates on any new O xyContin related overdose or opioid use disorder
diagnosis.” M cK insey advised Purdue on its strategies to obtain and maintain broad formulary
coverage for O xyContin w ith insurers and pharmacy benefit managers, even as payors began
reducing coverage for O xyContin as the opioid crisis mounted.
24.

Subsequently, in the wake o f hundreds o f thousands o f opioid deaths and thousands

o f lawsuits, M cK insey proposed a plan for Purdue’s exit from the opioid business whereby Purdue
would continue sellin g opioids as a w ay to fim d new Purdue ventures. A ccording to M cK insey, this
change was necessary because o f the negative events that m aterially com prom ised the Purdue
brand.
25.

M cK insey’s work for opioid manufacturers extended beyond Purdue. M cKinsey
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earned m illions o f dollars designing and im plem enting marketing programs for the country’s largest
opioid manufacturers, including Johnson & Johnson and Endo, increasing the sale and use o f
opioids in M aine. M cK insey designed and im plem ented for other opioid manufacturers marketing
plans sim ilar to those it created for Purdue.
26.

At the sam e tim e M cK insey was working for opioid com panies, M cK insey also

consulted with governm ents and non-profits working to abate the raging opioid crisis— a crisis that
M cK insey’s own research showed w as caused in large part by prescription opioids,
27.

There are indications that individuals at M cK insey considered destroying or deleting

docum ents related to their work for Purdue.
28.

In 2019, M cK insey announced that it no longer worked for Purdue or other opioid

manufacturers. But the harm created by M cK insey’s marketing plans for opioid manufacturers has
not stopped.
29.

O pioids have killed hundreds in M aine, and continue to ravage the liv es o f many

more, creating one o f the largest public health epidem ics in the country’s history. E conom ically, the
toll is equally grim. The opioid crisis has forced M aine to pay m illions o f dollars for increased costs
in health care, child w elfare, crim inal justice, and many other programs needed to abate the
epidemic.
30.

M onths after M cK insey stopped its opioid work, Purdue filed for bankruptcy. M ore

than a hundred thousand individuals filed claim s for personal injuries. States and local governments
filed claim s for trillions o f dollars incurred as a result o fth e opioid crisis. Another M cK insey client,
opioid manufacturer M allinckrodt pic, sim ilarly filed for bankruptcy protection in October 2020.
31.

In 2019, an Oklahoma state court found that M cKinsey client Johnson & Johnson

helped cause the opioid epidem ic in Oklahoma, ordering it to pay $465 m illion to help abate the crisis.
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32.

In 2020, Purdue pleaded guilty to three felonies as a result o f conduct spanning a

decade - from 2007 to 2017 - during w hich Purdue worked side-by-side w ith M cK insey to design
and implement marketing cam paigns to increase dangerous opioid sales.
33.

In 2020, Purdue and the m embers o f the Sackler fam ily who owned Purdue also

settled civil claim s by the Department o f Justice for hundreds o f m illions o f dollars. The materials
filed in connection w ith that plea and settlem ent agreem ents contain a statement o f facts regarding
M cK insey’s conduct and involvem ent in the conduct leading to the civil claim s against Purdue and

)

the Sackler fam ily.

IV.

CLAIM FOR RELIEF

Violation of the Maine
Unfair Trade Practices Act,
5 MR.S. § 207
(Unfairness)
34.

P lain tiff realleges and incorporates by reference each and every allegation contained

in the preceding paragraphs as i f they were set out herein.
35.

In the course o f its business, M cK insey unfairly and unconscionably worked with

certain o f its opioid manufacturing clients to aggressively promote and sell more opioids to more
patients for longer periods o f tim e.
36.

Such actions constitute unfair and unconscionable trade practices that are prohibited

by 5 M .R .S.§207.
37.

The acts or practices described herein occurred in trade or com m erce as defined in 5

M .R.S. § 206(3).

V.

Request for Relief

WHEREFORE, P lain tiff respectfully requests that this Honorable Court enter an Order:
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a.

Adjudging and decreeing that M cKinsey has engaged in the acts or practices

complained o f herein, and that such constitute unfair acts or practices in violation o f 5 M .R .S,§207;
b.

Issuing a permanent injunction prohibiting M cK insey, its agents, servants, em ployees,

and all other persons and entities, corporate or otherw ise, in active concert or participation with any
o f them, from engaging in unfair trade practices;
c.

Ordering M cK insey to m ake such paym ents as are authorized by law to the state to

address the harms caused by M cK insey’s unfair trade practices and ordering M cK insey to pay all
costs for the prosecution and investigation o f this action including attorneys’ fees as provided in 5
M .R.S.§ 209; and
d.

Ordering such other and further relief as the Court may deem just and proper.

Dated: February j , 2021

R espectfully submitted,
AARON M. FREY
ATTORNEY GENERAL

Linda Conti, M e Bar N o. 3638
Brendan F.X . O’N eil, M e Bar N o 9900
A ssistant Attorneys General
6 State H ouse Station
Augusta, ME 04333
207 626 8800

Attorneys for Plaintiff
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SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-21-

STATE OF MAINE
KENNEBEC SS

STATE OF MAINE

)
)
)

Plaintiff,

)
)
)
)
)
)
)

V.

MCKINSEY & COMPANY, INC.
UNITED STATES,
Defendant.

CONSENT JUDGMENT

Plaintiff, the State o f Maine (the “State” or “P lain tiff’) has filed a Complaint for
permanent injunction, damages and other relief in this matter pursuant to the Maine Unfair Trade
Practices Act, 5 M .R.S. § 209 alleging that Defendant M cKinsey & Company, Inc. United States
(“M cKinsey” or “Defendant”), committed violations o f 5 M.R.S. §207. Plaintiff, by its counsel,
and M cKinsey, by its counsel, have agreed to the entry o f this Consent Judgment (“Judgment”)
by the Court without trial or adjudication o f any issue o f fact or law, and without finding or
admission o f wrongdoing or liability o f any kind.

IT IS HEREBY ORDERED THAT:
I. FINDINGS
A. For purposes o f this proceeding only, this Court has jurisdiction over the subject matter
o f this lawsuit and over the Parties (as defined below). This Judgment shall not be
construed or used as a waiver o f any jurisdictional defense McKinsey may raise in any
other proceeding.
B. The terms o f this Judgment shall be governed by the laws o f the State o f Maine.
C. Entiy o f this Judgment is in the public interest and reflects a negotiated agreement among
the Parties.

D. The Parties have agreed to resolve the issues resulting from the Covered Conduct (as
defined below) by entering into this Judgment.
E. M cKinsey has cooperated with the Signatory Attorney General’s (as defined below)
investigation and is w illing to enter into this Judgment regarding the Covered Conduct in
order to resolve the Signatory Attorney General’s claim s and concerns under the Maine
Unfair Trade Practices Act, 5 M.R.S. §207 as to the matters addressed in this Judgment
and thereby avoid significant expense, inconvenience, and uncertainty.
F. “M ultiState Executive Committee” means the Attorneys General and staffs representing
California, Colorado, Connecticut, Massachusetts, N ew York, North Carolina, Oregon,
Oklahoma, Tennessee, and Vermont.
G. The Signatory Attorney General acknowledges M cKinsey’s good faith and responsible
corporate citizenship in reaching this resolution.
H. M cKinsey is entering into this Judgment solely for the purpose o f settlement, and nothing
contained herein may be taken as or construed to be an admission or concession o f any
violation o f law, rule, or regulation, or o f any other matter o f fact or law, or o f any
liability or wrongdoing, all o f which M cKinsey expressly denies. M cKinsey does not
admit any violation o f the State Consumer Protection Laws (as defined below) and set
forth in footnote 1) and does not admit any wrongdoing that was or could have been
alleged by the Signatory Attorney General before the date o f the Judgment. No part o f
this Judgment, including its statements and commitments, shall constitute evidence o f
any liability, fault, or wrongdoing by M cKinsey.
I.

This Judgment shall not be construed or used as a waiver or limitation o f any defense
otherwise available to McKinsey in any other action, or o f M cKinsey’s right to defend
itself from, or make any arguments in, any other regulatory, governmental, private
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individual, or class claim s or suits relating to the subject matter or terms o f this
Judgment. This Judgment is made without trial or adjudication o f any issue o f fact or law
or finding o f liability o f any kind. Notwithstanding the foregoing, the Signatory Attorney
General may file an action to enforce the terms o f this Judgment.
J. N o part o f this Judgment shall create a private cause o f action or confer any right to any
third party for violation o f any federal or state statute except that the Signatory Attorney
General may file an action to enforce the terms o f this Judgment. It is the intent o f the
Parties that this Judgment shall not be binding or adm issible in any other matter,
including, but not lim ited to, any investigation or litigation, other than in connection with
the enforcement o f this Judgment. This Judgment is not enforceable by any persons or
entities besides the Signatory Attorney General, M cKinsey and this Court.

II. DEFINITIONS
The follow ing definitions shall be used in construing the Judgment:
A. “Covered Conduct” means any and all acts, failures to act, conduct, statements, errors,
om issions, events, breaches o f duty, services, advice, work, deliverables, engagements,
transactions, or other activity o f any kind whatsoever, occurring up to and including the
Effective Date arising from or related in any way to (i) the discovery, development,
manufacture, marketing, promotion, advertising, recall, withdrawal, distribution,
monitoring, supply, sale, prescribing, reimbursement, use, regulation, or abuse o f any
opioid, or (ii) the treatment o f opioid abuse or efforts to combat the opioid crisis, or (iii)
the characteristics, properties, risks, or benefits o f any opioid, or (iv) the spoliation o f any
materials in connection with or concerning any o f the foregoing.
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B. “Effective Date” means the date on which a copy o f the Judgment, duly executed by
McKinsey and by the Signatory Attorney General, is approved by, and becomes a
Judgment o f the Court.
C. “McKinsey” means McKinsey & Company, Inc. United States, a Delaware Corporation,
and all its current or former officers, directors, partners, employees, representatives,
agents, affiliates, parents, subsidiaries, operating companies, predecessors, assigns and
successors.
D. “Parties” means McKinsey and the Signatory Attorney General.
E. “Signatory Attorney General” means the Attorney General o f Maine, or his/her
authorized designee, who has agreed to this Judgment.
F. “Settling State” means the state that has agreed to this Judgment.
G. “State Consumer Protection Laws” means the consumer protection laws cited in footnote

1.'*
6

1ALABAMA - Alabama Deceptive Trade Practices Act § 8-19-1 et seq. (2002); ALASKA Alaska Unfair Trade Practices and Consumer Protection Act AS 45.50.471 - 45.50.561;
AMERICAN SAMOA - Consumer Protection Act, A.S.C.A. §§ 27.0401 et seq.; ARIZONA Consumer Fraud Act, A.R.S. §44-1521 et seq.; ARKANSAS - Arkansas Deceptive Trade
Practices Act, Ark. Code Ann. § 4-88-101, et seq.; CALIFORNIA - Bus. & Prof Code §§ 17200
et seq. and 17500 et seq.; COLORADO - Colorado Consumer Protection Act, Colo. Rev. Stat. §
6-1-101 et seq.; CONNECTICUT - Connecticut Unfair Trade Practices Act, Conn. Gen Stat. §§
4 2-110a through 42-1 lOq; DELAWARE - Delaware Consumer Fraud Act, Del. CODE ANN. tit.
6 , §§2511 to 2527; DISTRICT OF COLUMBIA, District o f Columbia Consumer Protection
Procedures Act, D.C. Code §§ 28-3901 et seq.; FLORIDA - Florida Deceptive and Unfair Trade
Practices Act, Part II, Chapter 501, Florida Statutes, 501.201 et. seq.; GEORGIA - Fair Business
Practices Act, O.C.G.A. Sections 10-1-390 et seq.; GUAM - Trade Practices and Consumer
Protection, 5 G.C.A. Ch. 32 et seq.; HAWAII - Uniform Deceptive Trade Practice Act, Haw.
Rev. Stat. Chpt. 481A and Haw. Rev. Stat. Chpt. 480; IDAHO - Idaho Consumer Protection Act,
Idaho Code § 48-601 et seq.; ILLINOIS - Consumer Fraud and Deceptive Business Practices
Act, 815 ILCS 505/2 et seq.; INDIANA - Deceptive Consumer Sales Act, Ind. Code §§ 24-50.5-0.1 to 24-5-0.5-12; IOWA - Iowa Consumer Fraud Act, Iowa Code Section 714.16;
KANSAS - Kansas Consumer Protection Act, K.S.A. 50-623 et seq.; KENTUCKY - Kentucky
Consumer Protection Act, KRS Ch. 367.110, et seq.; LOUISIANA - Unfair Trade-Practices and
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H. Any reference to a written document shall mean a physical paper copy of the document,
electronic version o f the document, or electronic access to such document.

HI. INJUNCTIVE RELIEF
It is ordered that:
A. McKinsey shall not accept any future engagements relating to the
discovery, development, manufacture, marketing, promotion, advertising, recall,
withdrawal, monitoring, sale, prescribing, use or abuse o f any

Consumer Protection Law, LSA-R.S. 51:1401, et seq.; MAINE - Unfair Trade Practices Act, 5
M.R.S.A. § 207 et seq.; MARYLAND - Maryland Consumer Protection Act, Md. Code Ann.,
Com. Law §§ 13-101 et seq.; MASSACHUSETTS - Mass. Gen. Laws c. 93A, §§ 2 and 4;
MICHIGAN - Michigan Consumer Protection Act, MCL § 445.901 et seq.; MINNESOTA Minn. Stat. §§325D.44, 325F.69; MISSISSIPPI - Mississippi Consumer Protection Act, Miss.
Code Ann.§ 75-24-1, et seq.; MISSOURI - Missouri Merchandising Practices Act, Mo, Rev.
Stat. §§ 407.010 et seq.; MONTANA - Montana Consumer Protection Act §§ 30-14-101 et seq.;
NEBRASKA - Consumer Protection Act, Neb. Rev. Stat. §§ 59-1601 et seq. and Uniform
Deceptive Trade Practices Act, Neb. Rev. Stat. §§ 87-301 et seq.;; NEW HAMPSHIRE - N H
RSA §358-A et seq; NEW JERSEY - New Jersey Consumer Fraud Act, NJSA 56:8-1 et seq.;
NEW MEXICO - NMSA 1978, § 57-12-1 et seq.; NEW YORK - General Business Law Art.
22-A, §§ 349-50, and Executive Law § 63(12); NORTH CAROLINA -N orth Carolina Unfair
and Deceptive Trade Practices Act, N.C.G.S. § 75-1.1, et seq.; NORTH DAKOTA - Unlawful
Sales or Advertising Practices, N.D. Cent. Code § 51-15-02 et seq.; NORTHERN MARIANA
ISLANDS - Consumer Protection Act, 4 N. Mar. I. Code §§ 5201 et seq.; OHIO - Ohio
Consumer Sales Practices Act, R.C. 1345.01, et seq.; OKLAHOMA - Oklahoma Consumer
Protection Act 15 O.S. §§ 751 et seq.; OREGON - Oregon Unlawful Trade Practices Act, Or.
Rev. Stat. § 646.605 et seq,; PENNSYLVANIA - Pennsylvania Unfair Trade Practices and
Consumer Protection Law, 73 P.S. 201-1 et seq.; PUERTO RICO - Puerto Rico Antitrust Act,
10 L.P.R.A. § 259; RHODE ISLAND - Deceptive Trade Practices Act, Rhode Island Gen. Laws
§ 6-13.1-1, et seq.; SOUTH CAROLINA - South Carolina Unfair Trade Practices Act, S.C.
Code Ann. § 39-5-10 et seq.; SOUTH DAKOTA - South Dakota Deceptive Trade Practices and
Consumer Protection, SDCL ch. 37-24; TENNESSEE - Tennessee Consumer Protection Act,
Tenn. Code Ann. 47-18-101 et seq.; TEXAS - Texas Deceptive Trade Practices-Consumer
Protection Act, Tex. Bus. And Com. Code 17.41, et seq.; UTAH - Consumer Sales Practices Act,
Utah Code Ann. §§ 13-11-1 et seq.; VERMONT - Vermont Consumer Protection Act, 9 V.S.A.
§ 2451, et seq.; VIRGIN ISLANDS - Virgin Islands Consumer Protection Law, 12A V.I.C. §§
101 et seq.; VIRGINIA-Virginia Consumer Protection Act, Va Code Ann. §59.1-196 et seq.;
W ISC O N SIN -W is. Stat. § 100.18 (Fraudulent Representations); WYOMING - Wyoming
Consumer Protection Act, Wyo. Stat. Ann. §§ 40-12-101 through -114.
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Opioid or other opioid-based Schedule II or III controlled substance;
B. Nothing in Section III.A above is intended to prohibit McKinsey from offering its
services to: ( 1 ) clients who, as part o f their overall business, develop, manufacture,
market, promote, advertise, recall, withdraw, distribute, monitor, supply, sell or prescribe
opioids or other opioid-based Schedule II or III controlled substances, so long as the
subject matter o f the engagement does not specifically relate to opioids or other opioidbased Schedule II or III controlled substances; or (2) health care providers, health plans,
non-profit entities, governments, and quasi-governmental agencies, or any other client
that is not a pharmaceutical manufacturer, for purposes o f addressing a humanitarian
health crisis, drug abuse prevention, treatment, and mitigation or abatement efforts, or
other public health benefit;
C. Within eighteen months o f the Effective Date for paragraph 4 below, and within twentyfour months o f the Effective Date for paragraphs 1-3 below, McKinsey shall develop and
implement a document retention policy that provides as follows:
1. McKinsey shall maintain a centralized document storage system (“Storage
System”) such as a document management system or a file sharing platform.
2. Unless prohibited by state, federal, or foreign law, McKinsey shall require its
partners and employees, to the extent possible on a best-efforts basis, to create
and maintain a final working papers file (“Final Working Papers File”) relating to
client engagements on the Storage System. The Final Working Papers File shall
include, but not be limited to, letters o f proposal, contracts, memoranda, invoices,
contracted deliverables, and close-out memoranda.
3. McKinsey shall retain the Final Working Papers File for a minimum o f seven
years.
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4. McKinsey shall retain all communications and documents exchanged on any
electronic mail (including associated attachments) or instant message system that
McKinsey authorizes its personnel to use for five years;
5. Nothing in this section shall prevent McKinsey from: (a) deleting documents or
data as required by any state, federal, or foreign law or regulation, or (b) deleting
documents or data as contractually required by a third party where such
contractual requirement is reasonably necessary to allow the third party to comply
with any state, federal, or foreign law or regulation.
D. McKinsey shall implement a written policy requiring the termination o f any employee
that engages in the intentional spoliation o f evidence for an improper purpose;
E. In the next calendar year after the Effective Date, McKinsey shall include in the annual
acknowledgement that all McKinsey partners are required to certify a section describing
the terms and conditions o f this Judgment, and McKinsey shall further hold additional
annual training for partners in the Pharmaceuticals & Medical Products practice
concerning the terms and conditions o f this Judgement;
F. Revisions to Client conflict policy pertaining to Government Clients (defined below),
which shall be implemented within 60 days o f the Effective Date.
1. McKinsey agrees to revise its conflict policy pertaining to potential engagements by
any Settling State, county government, or municipal government (or any government
agency o f the aforementioned) (“Government Client”) to require a written disclosure
o f any material conflict (“Conflict Disclosure”) when (A) responding in writing to a
request for proposal; (B) formally proposing work; (C) tendering an engagement
letter to a Government Client; or (D) beginning work for a Government Client in the
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absence o f an engagement letter, proposal, or request for proposal, whichever occurs
first (“Triggering Event”).
2. A material conflict exists for purposes of this Section III.F when, at the time o f any
Triggering Event, McKinsey is advising or in the past three years has previously
advised an industry client on work which, in the view o f a neutral and detached
observer, is or was materially adverse to the work McKinsey would perform for the
Government Client, such that when McKinsey is working or has worked to advance
the goals or interests o f the industry client it is likely to harm the goals or interests it
is working to advance o f the Government Client.
3. Within 90 days o f the Effective Date, McKinsey shall review each current
engagement with a Government Client and provide a Conflict Disclosure where it
would be otherwise required under this Section III.F for a new Government Client.
4. Nothing in this Section III.F shall supersede or affect any legal or contractual
obligation McKinsey may have pertaining to confidentiality, conflicts, or
engagement o f clients (“Client Obligations”). The Conflict Disclosure shall not
require McKinsey to violate any confidentiality obligations McKinsey has with its
clients, and McKinsey satisfies its obligations under this section by providing a
Conflict Disclosure (A) identifying the relevant industry; and (B) generally
describing the work McKinsey performs for its industry client (without identifying
its client). If for whatever reason McKinsey determines that its Client Obligations
preclude a Conflict Disclosure, McKinsey agrees to decline the work for the
Government Client.
G. McKinsey shall not use, assist, or employ any Third Party to engage in any activity that
McKinsey itself would be prohibited from engaging in pursuant to this Judgment.
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H. The foregoing injunctive terms may be amended by agreement between McKinsey and
the State o f Maine without this Court’s approval or amendment o f this Judgment.
IV. PUBLIC ACCESS TO MCKINSEY DOCUM ENTS
It is ordered that:
A. Docum ents Subject to Publie Disclosure
1.

The following documents shall be produced by McKinsey to each Settling State and are

subject to public disclosure in perpetuity as part o f a document disclosure program, except for
the redactions authorized by Section B:
All non-privileged documents McKinsey produced to any o f the Settling States in response to
investigative demands or other formal or informal requests related to opioids in 2019,2020, or
2021, prior to the date o f this Judgment, that fall within the following categories:
a. All communications with Purdue Pharma LP (“Purdue”);
b. All documents reflecting or concerning McKinsey’s work for Purdue;
c. All communications with Endo Pharmaceuticals (“Endo”), Johnson & Johnson, or
Mallinckrodt Pharmaceuticals (“Maliinckrodt”) related to opioids;
d. All documents reflecting or concerning McKinsey’s work related to opioids for Endo,
Johnson & Johnson, or Mallinckrodtj
e. All documents and communications sent or received by individual consultants agreed
upon by McKinsey and the Settling States related to opioids or the opioid crisis;
f.

AH documents listed by Bates number in Appendix A.
2.

A ll documents produced under this provision shall be provided in electronic format

with all related metadata. McKinsey and the Settling States will work cooperatively to develop
technical specifications for the productions.
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B. Information That May Be Redacted
The following categories o f information are exempt from public disclosure:
1. Information subject to trade secret protection. A “trade secret” is information, including a
formula, pattern, compilation, program, device, method, technique or process, that (a) derives
independent economic value, actual or potential, from not being generally known to the public or
to other persons who can obtain economic value from its disclosure and use; and (b) is the
subject o f efforts that are reasonable under the circumstances to maintain its secrecy. Even if the
information falls within the definition, “trade secret” does not include information reflecting
opioid sales or promotional strategies, tactics, targeting, or data, or internal communications
related to sales or promotion of opioidsr
2. Confidential personal information. “Confidential personal information” means individual
Social Security or tax identification numbers, personal financial account numbers, passport
numbers, driver license numbers, home addresses, home telephone numbers, personal email
addresses, and other personally identifiable information protected by law from disclosure.
“Confidential personal information” does not include the names o f officers, directors, employees,
agents, or attorneys o f McKinsey, Purdue, Endo, Johnson & Johnson, or Mallinckrodt, or o f a
government agency.
3. Information that is inappropriate for public disclosure because it is subject to personal privacy
interests recognized by law (e.g., HIPAA), or contractual rights o f third parties (including
McKinsey’s clients) that McKinsey may not abrogate. McKinsey shall make its best efforts to
ensure that disclosure into the document repository is not limited or prohibited by contractual
rights o f Purdue with regard to any documents, or by contractual rights o f Endo, Johnson &
Johnson, or Mallinckrodt with regard to documents related to opioids.
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4. Information regarding McKinsey partners’ or employees’ personal or professional matters
unrelated to McKinsey or opioids, including but not limited to emails produced by McKinsey
custodians discussing vacation or sick leave, family, or other personal matters.

C. Redaction of Documents Containing Protected Information
1. Whenever a document contains information subject to a claim o f exemption pursuant to
Section B , McKinsey shall produce the document in redacted form. Such redactions shall
indicate that trade secret and/or private information, as appropriate, has been redacted.
Redactions shall be limited to the minimum redactions possible to protect the legally recognized
individual privacy interests and trade secrets identified above.
2. McKinsey shall produce to each Settling State a log noting each document redacted. The log
shall also provide fields stating the basis for redacting the document, with sufficient detail to
allow an assessment o f the merits o f the assertion. The log is subject to public disclosure in
perpetuity. The log shall be produced simultaneously with the production o f documents required
by Section IV.F.
3. In addition to the redacted documents, McKinsey shall, upon any Settling State’s request, also
produce all documents identified in Section IV.A above in unredacted form to such Settling State
at the same time. The redacted documents produced by McKinsey may be publicly disclosed in
accordance with Section IV.E below. The unredacted documents produced by McKinsey to a
Settling State shall be available only to such State unless McKinsey’s claim o f exemption under
Section IV.B is successfully challenged in accordance with Section IV.C.4 or the trade secret
designation expires in accordance with Section IV.D.
4. Anyone, including members o f the public and the press, may challenge the appropriateness o f
redactions by providing notice to McKinsey and a Settling State, which Settling State shall
review the challenge and inform McKinsey o f whether the challenge has sufficient merit to
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warrant triggering the remaining provisions o f this paragraph. If the challenge is not resolved by
agreement, it must be resolved in the first instance by a third party jointly appointed by the
Settling State and McKinsey to resolve such challenges. The decision o f the third party may be
appealed to a court with enforcement authority over this Judgment. If not so appealed, the third
party’s decision is final. In connection with such challenge, a Settling State may provide copies
o f relevant unredacted documents to the parties or the decisionmaker, subject to appropriate
confidentiality and/or in camera review protections, as determined by the decisionmaker.

D. Review of Trade Secret Redactions
Seven years after McKinsey completes the production o f its documents in accordance with
Section IV.F and upon notice by a Settling State, McKinsey shall review all trade secret

;

assertions made in accordance with Section IV.Br-The newly unredacted documents may then be
publicly disclosed by a Settling State in accordance with Section IV.E. McKinsey shall produce
to each Settling State an updated redaction log justifying its designations o f the remaining trade
secret redactions.

E. Public Disclosure through a Document Repository
Each Settling State may publicly disclose all documents covered by Section IV.A through a
public repository maintained by a governmental, non-profit, or academic institution. Each
Settling State may specify the terms o f any such repository’s use o f those documents, including
allowing the repository to index and make searchable all documents subject to public disclosure,
including the metadata associated with those documents. When providing the documents
covered by Section IV.A to a public repository, no Settling State shall include or attach within
the document set any characterization o f the content o f the documents. For the avoidance of
doubt, nothing in this paragraph shall prohibit any Settling State from publicly discussing the
documents covered by Section IV.A.
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F. Timeline for Production
McKinsey shall produce all documents required by Section IV.A within nine months from the
Effective Date.

G. Costs
The Settling States may allocate funds from the Settlement to fund the allocable share o f all
reasonable costs and expenses associated with the public disclosure and storage o f McKinsey’s
documents through any public repository,
V. PAYMENT
1.

McKinsey shall pay a total amount o f $573,919,331 (“the Settlement Amount”). Of the

Settlement Amount, $558,919,331 shall be allocated among the Settling States as agreed to by
the Settling States. It is the intent o f the Parties that the $558,919,331 paid to the participating
States will be used, to the extent practicable, to remediate the harms caused to the Settling States
and their citizens by the opioid epidemic within each State and to recover the costs incurred by
the Settling State in investigating and pursuing these claims .2 McKinsey shall pay the
$15,000,000 balance o f the Settlement Amount to the National Association o f Attorneys General
(“NAAG Fund”). The NAAG Fund shall be used: first, to reimburse NAAG for the costs and
expenses o f the States’ opioid investigations in the amount o f $7,000,000 and second to
reimburse participating States for documented costs and expenses associated with the
investigation o f McKinsey submitted by or before March 1,2021, subject to reasonable
parameters to be set by NAAG. The remaining balance o f the NAAG Fund shall be used to fund

2 Maine’s share o f the settlement is $3,139,915.00. The payment to the State o f Maine shall be deposited to the
special revenue account described in 5 M.R.S, § 203-A to be used by the Attorney General pursuant to that statute for
opioid remediation purposes that are evidence based, such as expanding availability o f treatment, including
Medication Assisted Treatment (MAT) for Opioid Use Disorder (OUD) and any co-occurring substance use or mental
health issues, supportive housing, recovery case management and residential treatment, addressing the needs o f
persons involved in the criminal justice system who have OUD, and paying costs o f litigating future cases arising
under Maine’s consumer protection laws, including costs for experts and personnel.
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the establishment o f an online repository of opioid industry documents for the benefit o f the
public.
2.

McKinsey shall pay a total amount o f $573,919,331 asfollows: 1) the initial payment o f

$478,266,111 including the $15,000,000 payment to NAAG, shall be paid by 60 days after the
Effective Date; 2) the second payment o f $23,913,305 shall be paid no later than one year from
the date o f the initial payment; 3) the third payment o f $23,913,305 shall be paid no later than
two years from the date o f the initial payment; 4) the fourth payment o f $23,913,305 shall be
paid no later than three years from the date o f the initial payment; and 5) the fifth payment o f
$23,913,305 shall be paid no later than four years from the date o f the initial payment.
3.

McKinsey will not seek indemnification from any entity with respect to this Judgment,

provided, however, that the foregoing limitation shall not be construed to apply to any claim by
McKinsey under any policies or contracts of insurance insuring McKinsey.

VI.

ENFORCEMENT

A. For the purposes of resolving disputes with respect to compliance with this Judgment,
should any o f the Signatory Attorneys General have a reasonable basis to believe that
McKinsey has engaged in a practice that violates a provision o f this Judgment subsequent
to the Effective Date, then such Signatory Attorney General shall notify McKinsey in
writing o f the specific objection, identify with particularity the provision o f this
Judgment/Order that the practice appears to violate, and give McKinsey 30 days to
respond to the notification; provided, however, that a Signatory Attorney General may
take any action if the Signatory Attorney General believes that, because o f the specific
practice, a threat to the health or safety o f the public requires immediate action.
B. Upon receipt o f written notice, McKinsey shall provide a good faith written response to
the Signatory Attorney General’s notification, containing either a statement explaining
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why McKinsey believes it is in compliance with the Judgment, or a detailed explanation
o f how the alleged violation occurred and a statement explaining how McKinsey intends
to remedy the alleged breach. Nothing in this section shall be interpreted to limit the
State o f Maine’s civil investigative demand (“CED”) or investigative subpoena authority,
to the extent such authority exists under applicable law, and McKinsey reserves all o f its
rights in responding to a CID or investigative subpoena issued pursuant to such authority.
C. The Signatory Attorney General may agree, in writing, to provide McKinsey with
additional time beyond the 30 days to respond to a notice provided under section V.A.
above without Court approval.
D. Upon giving McKinsey 30 days to respond to the notification described above, the
Signatory Attorney General shall also be permitted reasonable access to inspect and copy
relevant, non-privileged, non-work product records and documents in the possession,
custody, or control o f McKinsey that relate to McKinsey’s compliance with each
provision o f this Judgment/Order pursuant to that State’s CID or investigative subpoena
authority.
E. The Signatory Attorney General may assert any claim that McKinsey has violated this
Judgment in a separate civil action to enforce compliance with this Judgment, or may
seek any other relief afforded by law for violations o f the Judgment, but only after
providing McKinsey an opportunity to respond to thé notification described in paragraph
V.A above; provided, however, that a Signatory Attorney General may take any action if
the Signatory Attorney General believes that, because o f the specific practice, a threat to
the health or safety o f the public requires immediate action.
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VII. RELEASE
A. Released Claims. By its execution o f this Judgment, the State o f Maine releases and
forever discharges McKinsey and its past and present officers, directors, partners,
employees, representatives, agents, affiliates, parents, subsidiaries, operating companies,
predecessors, assigns and successors (collectively, the “Releasees”) from the following:
all claims the Signatory Attorney General is authorized by law to bring arising from or
related to the Covered Conduct, including, without limitation, any and all acts, failures to
act, conduct, statements, errors, omissions, breaches o f duty, services, advice, work,
engagements, events, transactions or other activity o f any kind whatsoever occurring up
to and including the effective date o f the Judgment. Released claims will include,
without limitation, claims that were or could have been brought by a Settling State under
its State’s consumer protection and unfair trade practices law, RICO laws, false claims
laws and claims for public nuisance, together with any related common law and equitable
claims for damages or other relief.
B. Claims Not Covered: Notwithstanding any term o f this Judgment, specifically reserved
and excluded from the release in Paragraph VII. A, as to any entity or person, including
Released Parties, are any and all o f the following:
1.

Any criminal liability that any person and/or entity, including Released Parties, has
or may have to the State o f Maine.

2.

Any civil or administrative liability that any person and/or entity, including Released
Parties, has or may have to the State o f Maine not covered by the release in
Paragraph V.A above, including the following claims:
(a) state or federal antitrust violations;
(b) any claims arising under state tax laws;
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(c) any claims arising under state securities laws;
(d) any action to enforce this consent judgment and any subsequent related
orders and judgments.
3.

Any liability under the State o f Maine State Consumer Protection Laws which any
person and/or entity, including Released Parties, has or may have to individual
consumers. Nothing herein precludes the Released Party from asserting any claims
or defenses that may be available to it under the law in any court action.

VIII. ADDITIONAL PROVISIONS
A. Nothing in this Judgment shall be construed to authorize or require any action by
McKinsey in violation o f applicable federal, state, or other laws.
B. Modification. This Judgment may be modified by a stipulation o f the Parties as
approved by the Court, or by court proceedings resulting in a modified judgment o f the
Court, except to the extent as otherwise provided herein. For purposes o f modifying this
Judgment, McKinsey may contact any member o f the MultiState Executive Committee
for purposes o f coordinating this process.
C. The acceptance o f this Judgment by the State o f Maine shall not be deemed approval by
the State o f Maine o f any o f McKinsey’s business practices. Further, neither McKinsey
nor anyone acting on its behalf shall state or imply, or cause to be stated or implied, that
the State o f Maine or any other governmental unit o f the State o f Maine has approved,
sanctioned or authorized any practice, act, or conduct o f McKinsey.
D. Any failure by any party to this Judgment to insist upon the strict performance by any
other party o f any o f the provisions of this Judgment shall not be deemed a waiver of any
o f the provisions o f this Judgment, and such party, notwithstanding such failure, shall
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have the right thereafter to insist upon the specific performance o f any and all o f the
provisions o f this Judgment.
E. Entire Agreement: This Judgment represents the full and complete terms o f the settlement
entered into by the Parties hereto, except as the parties have otherwise agreed. In any
action undertaken by the Parties, no prior versions o f this Judgment and no prior versions
o f any o f its terms that were not entered by the Court in this Judgment, may be introduced
for any purpose whatsoever.
F. Jurisdiction: This Court retains jurisdiction o f this Judgment and the Parties hereto for the
purpose o f enforcing and modifying this Judgment and for the purpose o f granting such
additional relief as may be necessary and appropriate.
G. If any provision o f this Judgment shall be held unenforceable, the Judgment shall be
construed as if such provision did not exist.
H. Counterparts: This Judgment may be executed in counterparts, and a facsimile or .pdf
signature shall be deemed to be, and shall have the same force and effect as, an original
signature.
I.

Notice: All Notices under this Judgment shall be provided to the following via email and
Overnight Mail:
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Defendant:
James Bernard, Esq.
Stroock & Stroock & Lavan LLP
180 Maiden Lane
New York, NY 10038
MAINE ATTORNEY GENERAL
AARON M. FREY

Linda Conti Me. Bar No. 3638
Brendan F.X. O’Neil, Bar No. 9900
Assistant Attorneys General
6 State House Station
Augusta, ME 04333
207 626-8800
Attorneys for Plaintiff

APPROVAL BY COURT
APPROVED FOR FILING and SO ORDERED th is_____ day o f ______, 2021

Judge

Approved:
For Defendant McKinsey & Company, Inc. United States

Jonathan Slonim
Assistant Secretary
McKinsey & Company, Inc. United States
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February 4, 2021
Date

Local Counsel for McKinsey & Company, Inc. United States

February 4, 2021
Date

Elaine Epstein
Ingrid Martin
Todd & Weld LLP
One Federal Street
Boston, MA 02110
Ph (617) 624-4761
eepstein@toddweld.com
imartin@toddweld.com
For Plaintiff $tate o f Maine
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'/V/
Date

Linda Conti, ME Bar No. 3638
Brendan F.X. O’Neil, Bar No. 9900
Assistant Attorneys General
6 State House Station
Augusta, ME 04333
207 626 8800
Attorneys for Plaintiff
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Appendix A
MCK-MAAG-1544652
MCK-MAAG-1570202
MCK-MAAG-1571908
MCK-MAAG-1589937
MCK-MAAG-1589940
MCK-MAAG-1590287
MCK-MAAG-1590603
MCK-MAAG-1590746
MCK-MAAG-1591211
MCK-MAAG-1597314
MCK-MAAG-1603322
MCK-MAAG-1613230
MCK-MAAG-1624788
MCK-MAAG-1630605
MCK-MAAG-1670515
MCK-MAAG-1670516
MCK-MAAG-2077068
MCK-MAAG-2152090
MCK-MAAG-2719249
MCK-MAAG-2787084
MCK-MAAG-2790782
MCK-MAAG-2805191
MCK-MAAG-2808669
MCK-MAAG-2808670
MCK-MAAG-2837394
MCK-M AAG-283 7395
MCK-MAAG-2839073
MCK-MAAG-2839075
MCK-MAAG-2841364
MCK-MAAG-2881476
MCK-MA AG-2886471
MCK-MAAG-2886477
MCK-MAAG-2893030
MCK-MAAG-2908880
MCK-MAAG-2908881
MCK-MAAG-2908885
MCK-MAAG-2909113
MCK-MA AG-2909114
MCK-MAAG-2911814
MCK-MAAG-2911815
MCK-MAAG-2921834
MCK-MAAG-2921835
MCK-MAAG-2966989
MCK-MAAG-2991109
MCK-MA AG-3040652
MCK-MAAG-3041706

MCK-MAAG-3041708
MCK-MA AG-3152316
MCK-MAAG-3168910
MCK-M AAG-3199855
MCK-MAAG-3217737
MCK-M AAG-3219322
MCK-MAAG-3222927
MCK-MAAG-3222929
MCK-MAAG-3309412
MCK-MAAG-3333173
MCK-MAAG-3384390
MCK-MAAG-3384391
MCK-MAAG-3391026
MCK-MAAG-3391027
MCK-MA AG-3406104
MCK-MA AG-3413038
MCK-MAAG-3414178
MCK-MAAG-3453527
MCK-MAAG-3492592
MCK-MAAG-3526344
MCK-MAAG-3526345
MCK-MAAG-3546336
MCK-MAAG-3546337
MCK-MAAG-3546340
MCK-MAAG-3546609
MCK-MAAG-3546612
MCK-MAAG-3555902
MCK-MAAG-3630697
MCK-MAAG-3634278
MCK-MAAG-3642963
MCK-MAAG-3642964
MCK-MAAG-3643215
MCK-MAAG-3645435
MCK-MAAG-3665829
MCK-MAAG-3696418
MCK-MAAG-3696420
MCK-MA AG-3749814
MCK-MAAG-3751212
MCK-MAAG-3751213
MCK-MAAG-3795707
MCK-MAAG-3796164
MCK-MAAG-3796165
MCK-MAAG-3804863
MCK-MAAG-3 804864
MCK-MAAG-3827062
MCK-MAAG-3 855056
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MCK-MAAG-3 863611
MCK-MAAG-3 895137
MCK-MAAG-3896012
MCK-MAAG-3921039
MCK-MAAG-3954641
MCK-MAAG-4190664
MCK-MAAG-4190665
MCK-MAAG-488683 5
MCK-MAAG-4886836
MCK-MA AG-4892126
MCK-MAAG-4892127
MCK-MAAG-4905287
MCK-MAAG-4905288
MCK-MAAG-0000840
MCK-MAAG-0000842
MCK-MAAG-0001882
MCK-MAAG-0001888
MCK-MAAG-0002240
MCK-MAAG-0002291
MCK-M A AG-0008858
MCK-MAAG-0009372
MCK-MAAG-0009806
MCK-MA AG-0015899
MCK-MA AG-0016100
MCK-MAAG-0016110
MCK-MAAG-0016542
MCK-MAAG-0016588
MCK-MAAG-0016637
MCK-MAAG-0016638
MCK-MAAG-0016768
MCK-MAAG-0017303
MCK-MAAG-0017306
MCK-MAAG-0017817
MCK-MAAG-0019859
MCK-MAAG-0019861
MCK-MAAG-0019862
MCK-MAAG-0019866
MCK-MAAG-0019876
MCK-MAAG-0019901
MCK-MAAG-0019927
MCK-MAAG-0019930
MCK-MAAG-0019953
MCK-MAAG-0019961
MCK-MAAG-0020127
MCK-MA AG-0020210
MCK-MAAG-0020223

MCK-MAAG-0020224
MCK-MAAG-0020387
MCK-MAAG-0024140
MCK-MAAG-0024283
MCK-MAAG-0028129
MCK-MAAG-0029267
MCK-MAAG-0030496
MCK-MA AG-0035715
MCK-MAAG-0038619
MCK-MA AG-0040658
MCK-MAAG-0040767
MCK-MAAG-0044626
MCK-MAAG-0044800
MCK-MAAG-0044814
MCK-MAAG-0044827
MCK-MAAG-0044833
MCK-MAAG-0044840
MCK-MAAG-0044842
MCK-MAAG-0044845
MCK-MAAG-0044860
MCK-MAAG-0044876
MCK-MAAG-0044938
MCK-MAAG-0045031
MCK-MAAG-0045060
MCK-MA AG-0045560
MCK-MAAG-0046143
MCK-MA AG-0052510
MCK-MAAG-0055337
MCK-MAAG-0063755
MCK-MA AG-0063 880
MCK-MAAG-0080178
MCK-MAAG-0084960
MCK-MAAG-0084962
MCK-MA AG-0084972
MCK-MAAG-0087880
MCK-MA AG-0087931
MCK-MAAG-0087932
MCK-MAAG-0088085
MCK-MAAG-0088172
MCK-MAAG-0088201
MCK-MAAG-0088316
MCK-MAAG-0088344
MCK-MAAG-0089908
MCK-MAAG-0089909
MCK-MAAG-0089914
MCK-MAAG-0089920

MCK-MAAG-0089966
MCK-MAAG-0092665
MCK-MAAG-0092695
MCK-MAAG-0093089
MCK-MAAG-0093346
MCK-MAAG-0094364
MCK-MAAG-0095439
MCK-MAAG-0095557
MCK-MAAG-0095587
MCK-MAAG-0095695
MCK-MAAG-0096066
MCK-MAAG-0096067
MCK-MAAG-0096210
MCK-MAAG-0096243
MCK-MAAG-0097005
MCK-MAAG-0097006
MCK-MAAG-0099242
MCK-MAAG-0099812
MCK-MAAG-0100021
MCK-MAAG-0102192
MCK-MAAG-0102541
MCK-MAAG-0102567
MCK-MAAG-0102568
MCK-MAAG-0103224
MCK-MAAG-0103273
MCK-MAAG-0105775
MCK-MAAG-0106442
MCK-MAAG-0111862
MCK-MAAG-0112085
MCK-MAAG-0112221
MCK-MAAG-0112310
MCK-MAAG-0112331
MCK-MAAG-0112490
MCK-MAAG-0112491
MCK-MAAG-0112527
MCK-MAAG-0112528
MCK-MAAG-0112710
MCK-MAAG-0112986
MCK-MAAG-0113407
MCK-MAAG-0113412
MCK-MAAG-0115124
MCK-MAAG-0116789
MCK-MAAG-0117119
MCK-MAAG-0117203
MCK-MAAG-0117327
MCK-MAAG-0117437
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MCK-MAAG-0117438
MCK-MAAG-0117452
MCK-MAAG-0117454
MCK-MAAG-0117473
MCK-MAAG-0117492
MCK-MAAG-0117614
MCK-MAAG-0117619
MCK-MAAG-0117733
MCK-MAAG-0117830
MCK-MAAG-0117869
MCK-MAAG-0117977
MCK-MAAG-0118841
MCK-MAAG-0119088
MCK-MAAG-0119155
MCK-MAAG-0119156
MCK-MAAG-0119178
MCK-MAAG-0119227
MCK-MAAG-0119359
MCK-MAAG-0119362
MCK-MAAG-0119363
MCK-MAAG-0119381
MCK-MAAG-0119459
MCK-MAAG-0119659
MCK-MAAG-0119722
MCK-MAAG-0119732
MCK-MAAG-0119743
MCK-MAAG-0120284
MCK-MAAG-0120285
MCK-MAAG-0120692
MCK-MAAG-0120693
MCK-MAAG-0120798
MCK-MAAG-0120804
MCK-MAAG-0120810
MCK-MAAG-0120814
MCK-MAAG-0122009
MCK-MAAG-0122064
MCK-MAAG-0124221
MCK-MAAG-0124222
MCK-MAAG-0128121
MCK-MAAG-0128451
MCK-MAAG-0128452
MCK-MAAG-0128552
MCK-MAAG-0128553
MCK-MAAG-0128578
MCK-MAAG-0136530
MCK-MAAG-0136552

MCK-MAAG-0140812
MCK-MAAG-0140826
MCK-MAAG-0141490
MCK-MAAG-0141572
MCK-MAAG-0143250
MCK-MAAG-0143818
MCK-MAAG-0144118
MCK-MAAG-0144142
MCK-MAAG-0148291
MCK-MAAG-0148308
MCK-MAAG-0149363
MCK-MAAG-0150137
MCK-MAAG-0152135
MCK-MAAG-0154714
MCK-MAAG-0156176
MCK-MAAG-0159054
MCK-MAAG-0159062
MCK-MAAG-0159070
MCK-MAAG-0159188
MCK-MAAG-0159238
MCK-MAAG-0159274
MCK-MAAG-0159278
MCK-MAAG-0159279
MCK-MAAG-0159283
MCK-MAAG-0159301
MCK-MAAG-0159317
MCK-MAAG-0159321
MCK-MAAG-0159327
MCK-MAAG-0159357
MCK-MAAG-0160262
MCK-MAAG-0160274
MCK-MAAG-0162838
MCK-MAAG-0200286
MCK-MAAG-0200325
MCK-MAAG-0200327
MCK-MAAG-0200329
MCK-MA AG-0200331
MCK-MAAG-0200333

MCK-MAAG-0200337
MCK-MAAG-0200339
MCK-MAAG-0200341
MCK-MAAG-0200343
MCK-MAAG-0201384
MCK-MA AG-0201387
MCK-MAAG-0201388
MCK-MAAG-02043 73
MCK-M AAG-0214791
MCK-MAAG-0215818
MCK-MAAG-0216610
MCK-MAAG-0218683
MCK-MAAG-0218685
MCK-MAAG-0218746
MCK-MAAG-0220378
MCK-MAAG-0221099
MCK-MAAG-0221100
MCK-MAAG-0221712
MCK-MAAG-0222056
MCK-MAAG-0222884
MCK-MAAG-0222947
MCK-MAAG-1000240
MCK-MAAG-1000241
MCK-MAAG-1001368
MCK-MAAG-1001369
MCK-MAAG-1001699
MCK-MAAG-1006207
MCK-MAAG-1006208
MCK-MAAG-1011097
MCK-MAAG-1013579
MCK-MAAG-1014049
MCK-MAAG-1024211
MCK-MAAG-1027204
MCK-MAAG-1027490
MCK-MAAG-1027539
MCK-MAAG-1037855
MCK-MAAG-1038327
MCK-MAAG-1039590
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MCK-MAAG-1041477
MCK-MAAG-1041765
MCK-MAAG-1042285
MCK-MAAG-1056710
MCK-MAAG-1056712
MCK-MAAG-1056717
MCK-MAAG-1056720
MCK-MAAG-1071121
MCK-MAAG-1071844
MCK-MAAG-1072941
MCK-MAAG-1073189
MCK-MAAG-1073190
MCK-MAAG-1073256
MCK-MAAG-1295952
MCK-MAAG-1305931
MCK-MAAG-1308573
MCK-MAAG-1392564
MCK-MAAG-1394243
MCK-MAAG-1402088
MCK-MAAG-1408283
MCK-MAAG-1408285
MCK-MAAG-1670515
MCK-MAAG-1670516
MCK-MA AG-3309412
MCK-MAAG-3413038
MCK-M AAG-3453527
MCK-MAAG-3526344
MCK-MAAG-3526345
MCK-MAAG-3751213
MCK-MAAG-3795707
MCK-MAAG-3863611
MCK-MAAG-3921039
MCK-MAAG-3954641
MCK-MAAG-4475742
MCK-MA AG-4782013
MCK-MAAG-4905287
MCK-MAAG-49052

